Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Cancer Res. 2014 Jan 1;74(1):15-23. doi: 10.1158/0008-5472.CAN-13-0544. Epub 2013 Dec 9.

A genetic mouse model of invasive endometrial cancer driven by concurrent loss of Pten and Lkb1 Is highly responsive to mTOR inhibition.

Author information

  • 1Authors' Affiliations: Department of Cancer Biology; Division of Women's Cancers, Department of Medical Oncology, Dana-Farber Cancer Institute; Departments of Biological Chemistry and Molecular Pharmacology and Systems Biology; Rodent Histopathology Core, DF/HCC, Harvard Medical School; Department of Surgery, Brigham and Women's Hospital; Division of Signal Transduction, Beth Israel Deaconess Medical Center, Boston; Novartis Institutes for Biomedical Research, Cambridge, Massacheusetts; Department of System Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas; and Novartis Institutes for Biomedical Research, Oncology Disease Area, Novartis Pharma AG, Basel, Switzerland.

Abstract

Signals from the tumor suppressors PTEN and LKB1 converge on mTOR to negatively regulate its function in cancer cells. Notably, both of these suppressors are attenuated in a significant fraction of human endometrial tumors. In this study, we generated a genetic mouse model of endometrial cancer driven by concomitant loss of these suppressors to gain pathophysiological insight into this disease. Dual loss of Pten and Lkb1 in the endometrial epithelium led to rapid development of advanced endometrioid endometrial tumors with 100% penetrance and short host survival. The tumors displayed dysregulated phosphatidylinositol 3-kinase (PI3K)/Akt and Lkb1/Ampk signaling with hyperactivation of mTOR signaling. Treatment with a dual PI3K/mTOR inhibitor, BEZ235, extended the time before tumor onset and prolonged overall survival. The PI3K inhibitor GDC-0941 used as a single agent reduced the growth rate of primary tumor implants in Pten/Lkb1-deficient mice, and the mTOR inhibitor RAD001 was unexpectedly as effective as BEZ235 in triggering tumor regression. In parallel, we also found that ectopic expression of LKB1 in PTEN/LKB1-deficient human endometrial cancer cells increased their sensitivity to PI3K inhibition. Together, our results demonstrated that Pten/Lkb1-deficient endometrial tumors rely strongly on deregulated mTOR signaling, and they provided evidence that LKB1 status may modulate the response of PTEN-deficient tumors to PI3K or mTOR inhibitors.

PMID:
24322983
[PubMed - indexed for MEDLINE]
PMCID:
PMC3982380
[Available on 2015/1/1]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire
    Loading ...
    Write to the Help Desk